Status:
UNKNOWN
Effect of Prophylactic Use of Silymarin on Hepatotoxicity Induced by Anti-tuberculosis Drugs
Lead Sponsor:
Seoul National University Hospital
Conditions:
Tuberculosis
Eligibility:
All Genders
35+ years
Phase:
NA
Brief Summary
Tuberculosis is a worldwide common infectious disease and effective first line anti-tuberculosis (TB) drugs were available such as isoniazid, rifampicin, ethambutol, and pyrazinamide. However, anti-TB...
Eligibility Criteria
Inclusion
- subjects who are diagnosed with tuberculosis based on microbiological, biomolecular, pathological, or radiographical findings and are expecting to be administered with anti-tuberculosis drugs including INH, RFP, or PZA.
- adults \>=35 years old
Exclusion
- basal AST \>40 IU/uL or ALT \>40 IU/uL
- pregnancy
- lactating women
- cases with history of adverse events to silymarin
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2013
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT01436929
Start Date
September 1 2011
End Date
December 1 2013
Last Update
December 17 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Deog Kyeom Kim
Seoul, South Korea, 156-707